Skip to content
Clinical Trials – home

Assistance Publique Hopitaux De Paris

Verified siteinfo

France Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris, France

  • 12 trials recruiting
  • Arteriosclerosis · Squamous cell carcinoma of head and neck · Acute hepatic failure
  • Adults and children

About Specializations

Assistance Publique Hopitaux De Paris in Paris, France specialises in clinical trials of conditions such as Arteriosclerosis, Squamous cell carcinoma of head and neck, Acute hepatic failure, Acute myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Disease Research

At Assistance Publique Hopitaux De Paris, a major focus is cardiology research across cardiovascular diseases, with studies in atherosclerotic cardiovascular disease, atrial fibrillation, heart failure, hypertrophic cardiomyopathy, and transcatheter aortic valve implantation-related care. These trials are designed to test new treatments, improve prevention, and reduce serious cardiac events.

  • Preventing major cardiovascular events in high-risk patients
  • Evaluating therapies for atrial fibrillation and stroke prevention
  • Studying heart failure, inflammation, and structural heart disease

The site is also involved in research on lipid-related risk factors such as elevated lipoprotein(a) and severe hypertriglyceridemia, reflecting a broad effort to improve long-term cardiovascular outcomes.

Neurology and Brain Health

Clinical trials in nervous system diseases at this Paris hospital include work on early Alzheimer’s disease, multiple sclerosis, idiopathic hypersomnia, and glioblastoma. The research aims to better understand disease progression, support symptom control, and assess whether new therapies can improve daily function and survival.

  • Testing treatments for early cognitive decline
  • Comparing disease-modifying approaches in relapsing multiple sclerosis
  • Improving diagnosis and management of aggressive brain tumors

The portfolio also includes studies of sleep-related disorders and advanced imaging tools, showing interest in both treatment and diagnosis within neurology.

Oncology and Hematology

A substantial part of the research landscape covers neoplasms and hemic and lymphatic diseases, including acute myeloid leukemia, myelodysplastic syndrome, B-cell malignancies, Richter syndrome, and several solid tumors such as head and neck cancer, prostate cancer, and renal cell carcinoma. These trials are focused on testing new cancer therapies, improving survival, and refining treatment strategies.

  • Evaluating novel combinations for blood cancers
  • Studying treatment options for recurrent or advanced solid tumors
  • Exploring ways to improve outcomes after surgery or standard therapy

The site also supports research into tumor imaging and device-based approaches, highlighting a strong interest in both cancer treatment and clinical innovation.

Immune, Inflammatory, and Autoimmune Disorders

Research in immune system diseases and related inflammatory conditions includes idiopathic inflammatory myopathy, Sjögren’s syndrome, uveitis, progressive multifocal leukoencephalopathy in immunocompromised patients, and acquired hemophagocytic syndrome. These studies aim to evaluate new therapies, control inflammation, and improve safety in complex immune-mediated illness.

  • Assessing treatment effectiveness in autoimmune and inflammatory disease
  • Studying eye inflammation and vision-threatening complications
  • Investigating immune-based approaches in critically ill or immunocompromised patients

This work reflects a broad interest in balancing immune modulation with patient safety across multiple specialties.

Digestive, Liver, and Metabolic Research

The site also conducts trials in digestive system diseases and nutritional and metabolic diseases, including hepatic encephalopathy, inflammatory liver adenomas, and severe hypertriglyceridemia. These studies are intended to improve symptom control, prevent complications, and evaluate new treatment options for liver and metabolic disorders.

  • Testing therapies to delay liver-related hospitalizations
  • Studying new approaches for inflammatory liver conditions
  • Evaluating treatments that lower metabolic and cardiovascular risk

At Assistance Publique Hopitaux De Paris, this area links internal medicine with cardiology through research on shared risk factors and long-term disease prevention.

Psychiatry, Rare Disorders, and Diagnostic Innovation

Additional trials span mental disorders and specialized diagnostic research, including treatment-resistant depression and advanced imaging for low-grade glioma. The goal is to test new therapeutic options while also improving how difficult-to-classify diseases are detected and characterized.

  • Exploring new options for difficult-to-treat depression
  • Improving imaging-based diagnosis in brain tumors
  • Supporting precision medicine across complex and uncommon conditions

This mix of psychiatric and diagnostic studies adds depth to the site’s broader research profile, showing engagement with both treatment development and better disease classification.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Num Voie 47 A 83, 47 Boulevard De L Hopital75013 ParisFrance
Recruiting now
12 trials
Conditions studied
35
Partner status
Verified site

More sites in ParisFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

33 clinical trials

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Nizubaglustat
  • Sponsor:Azafaros B.V.

Study Comparing Thymoglobulin and Grafalon for Preventing Graft Versus Host Disease in Elderly Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of Pembrolizumab for Progressive Multifocal Leukoencephalopathy in Immunocompromised Patients Without HIV

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Uveitis

Recruiting

Study Comparing Adalimumab and Mycophenolate Mofetil for Patients with Steroid-Dependent Non-Infectious Uveitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Glioblastoma

Recruiting

Study on Glioblastoma Recurrence: Comparing SonoCloud-9 with Carboplatin to Standard Treatments Lomustine or Temozolomide for Patients Undergoing Tumor Removal Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Carthera

Hypersomnia

Recruiting

Study on Melatonin and Light Therapy for Adults with Idiopathic Hypersomnia

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Melatonin
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Study on Protamine Sulfate to Reduce Neurological Events After Aortic Valve Implantation in Patients with Aortic Stenosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Protamine Sulfate
  • Sponsor:Assistance Publique Hopitaux De Paris

Glioma

Recruiting

Study on Fluorodopa (18F) for Diagnosing Low-Grade Glioma in Patients Without MRI Contrast Enhancement

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorodopa (18F)
  • Sponsor:CHRU De Nancy

Study on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lixudebart
  • Sponsor:Alentis Therapeutics AG

Study on the Safety and Effectiveness of VB10.16 and Pembrolizumab for Patients with HPV16-Positive Head and Neck Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Nykode Therapeutics ASA

Study of Glofitamab with Rituximab or Obinutuzumab and Drug Combination for Untreated Richter's Syndrome Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.